Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
type 1 diabetes mellitus |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS. |
17554260 |
LncRNADisease
|
prostate cancer |
N/A |
N/A |
N/A |
mutation |
Association identified by GWAS. |
19767753 |
LncRNADisease
|
Wilms' tumor |
qPCR, Northern blot etc. |
Wilms' tumor tissue |
up-regulated |
expression |
PEG8/IGF2AS and IGF2 were found to be overexpressed in Wilms' tumor samples, at levels over ten and a hundred times higher than that in normal kidney tissues neighboring the tumors, respectively. |
10731720 |
LncRNADisease Lnc2Cancer
|
Wilms' tumor |
qPCR, Northern blot etc. |
Wilms' tumor tissue |
down-regulated |
N/A |
IGF2-AS was expressed at levels comparable with IGF2 sense expression derived from promoters P1 and P2 in normal tissue and in breast, ovarian, and Wilms' tumor tissues. In Wilms' tumors that demonstrate maintenance of imprinting of IGF2, IGF2-AS was imprinted. |
12702581 |
LncRNADisease Lnc2Cancer
|
liver cancer |
qPCR, Northern blot etc. |
liver cancer tissue |
up-regulated |
expression |
Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. |
12702581 |
LncRNADisease Lnc2Cancer
|
hepatocelluar carcinoma |
qPCR, Southern blot etc. |
SMMC-7721 cell line |
differential expression |
N/A |
IGF-IR and IGF-IIR antisense genes could significantly restrain the malignant behavior of human hepatoma cells and might be useful in investigating a potential route for hepatocellular carcinoma gene therapy. |
12603530 |
LncRNADisease Lnc2Cancer
|
|